Abstract
Recent concern over existing drug-eluting stents, for the treatment of myocardial ischaemia, has led to the development of approaches that seek to inhibit restenosis while promoting the recovery of a functional endothelium. Prostacyclin analogues may be worthy candidates for use within a drug-eluting stent by virtue of their wide profile of vasoprotective effects. This article reviews recent developments in this area, and in so doing, reveals the future challenges for the further development of this technology.
| Original language | English |
|---|---|
| Pages (from-to) | 910-911 |
| Number of pages | 2 |
| Journal | Biochemical Society Transactions |
| Volume | 35 |
| Issue number | Part 5 |
| DOIs | |
| Publication status | Published - Nov 2007 |
| Event | Focus Topic at Life Sciences 2007 Conference - Glasgow, United Kingdom Duration: 9 Jul 2007 → 12 Jul 2007 |
Keywords
- drug-eluting stent
- human coronary artery
- prostacyclin
- prostanoid receptor
- restenosis
- smooth muscle cell proliferation
- neointima formation
- coronary-arteries
- coated stents
- iloprost
- pib
- proliferation
- receptors
- cells